References
- Akkaya C, Kaya B, Kotan Z, Sarandol A, Ersoy C, Kirli S. 2008. Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases. J Psychopharmacol. Ann Clin Psychiatry 14(3):163–173.
- Bushe C, Yeomans D, Floyd T, Smith SM. 2008a. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol 22(2 Suppl):56–62.
- Bushe C, Shaw M, Peveler RC. 2008b. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 22(2 Suppl):46–55.
- Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. 1994. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 120(10):817–820.
- Hamner M. 2002. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 14(3):163–73.
- Hummer M, Huber J. 2004. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 20(2):189–197.
- Mendhekar D, Lohia D. 2008. Amisulpride and galactorrhoea: Delayed or withdrawal? World J Biol Psychiatry 13:1–2.
- Mendhekar DN, Jiloha RC, Srivastava PK. 2003. Effect of risperidone on prolactinoma. Pharmacopsychiatry 37:41–42.
- Pal JK, Sarino WA. 2000. Effect of risperidone on prolactinoma growth in a psychotic woman. Psychosom Med 62: 736–738.
- Perroud N, Huguelet P. 2004. A possible effect of amisulpride on a prolactinoma growth in a woman with borderline personality disorder. Pharmacol Res 50(3):377–379.
- Szarfman A, Tonning JM, Levine JG, Doraiswamy PM. 2006. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 26(6):748–758.